ArticleCureus2025
Safety and Cost-Effectiveness of the FAM-DX Three-Dimensional CARTO Navigation System in Zero Fluoroscopy Electrophysiology Studies for Supraventricular Tachycardia: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The zero fluoroscopy (ZF) ablation technique reduces radiation exposure for both medical staff and patients but typically requires specialized navigation ablation catheters. The innovative FAM-DX Three-Dimensional CARTO Navigation System enables 3D mapping without the need for these specialized catheters. This study investigates the safety, feasibility, efficacy, and cost-effectiveness of using the FAM-DX system for ZF electrophysiology (EP) studies in patients with supraventricular tachycardia (SVT). Methods A retrospective analysis was performed at a single center on patients who underwent EP studies using the FAM-DX system between November 2021 and December 2023. Exclusion criteria included patients under 18, pregnant women, those with recent pacemaker implantation, and individuals requiring specific ablations. Clinical data, including patient characteristics, indications, procedure details, fluoroscopy use, ablation requirements, and any procedure-related adverse events, were collected. Results A total of 87 consecutive patients (mean age: 53 ± 18.9 years) were included in this retrospective cohort analysis. Of these, 86 patients (98.85%) successfully underwent ZF ablation using the FAM-DX 3D navigation system, with mapping conducted in various heart regions, including the right atrium, His bundle, coronary sinus, superior vena cava, and inferior vena cava. Only one patient required fluoroscopy due to vascular access issues. Notably, in 41% of cases (36 patients), the ablation catheter was not initially needed or used during the electrophysiological study, suggesting a potential cost-saving benefit given the catheter's cost of approximately $2,431. Conclusions Our study demonstrates that the FAM-DX system enables safe and efficient 3D mapping and ZF techniques for SVT EP studies. This cost-effective approach suggests that the use of ablation catheters may be unnecessary for certain patients. Further research is required to validate the broader adoption of ZF techniques and their application in more complex left-sided procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.